Genes (28)
Species: human : 28 | |
Human | FLCN | 201163 | folliculin | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | MLH3 | 27030 | mutL homolog 3 (E. coli) | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | AXIN2 | 8313 | axin 2 | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | EZR | 7430 | ezrin | Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. | Human | TP53 | 7157 | tumor protein p53 | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | TLR4 | 7099 | toll-like receptor 4 | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | TLR2 | 7097 | toll-like receptor 2 | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | AURKA | 6790 | aurora kinase A | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | RBL2 | 5934 | retinoblastoma-like 2 (p130) | Expression of the retinoblastoma-related gene Rb2/p130 is downregulated in atypical endometrial hyperplasia and adenocarcinoma. | Human | PTPRJ | 5795 | protein tyrosine phosphatase, receptor type, J | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | PLA2G2A | 5320 | phospholipase A2, group IIA (platelets, synovial fluid) | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | PIK3CA | 5290 | phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | PDGFRL | 5157 | platelet-derived growth factor receptor-like | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | ODC1 | 4953 | ornithine decarboxylase 1 | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | NRAS | 4893 | neuroblastoma RAS viral (v-ras) oncogene homolog | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | NME1 | 4830 | NME/NM23 nucleoside diphosphate kinase 1 | In this study, there was no immunostaining of normal endometria or of endometrial hyperplasia (including atypical endometrial hyperplasia) to support the hypothesis that expression of the nm23 gene product is related to the development of endometrial adenocarcinoma. In this study, there was no immunostaining of normal endometria or of endometrial hyperplasia (including atypical endometrial hyperplasia) to support the hypothesis that expression of the nm23 gene product is related to the development of endometrial adenocarcinoma. | Human | SMAD7 | 4092 | SMAD family member 7 | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | KRAS | 3845 | Kirsten rat sarcoma viral oncogene homolog | KRAS2 mutations have been detected in laser-capture microdissected atypical endometrial hyperplasia specimens arising concurrently with endometrial carcinoma | Human | IGFBP1 | 3484 | insulin-like growth factor binding protein 1 | Significantly higher IGFBP-1 concentrations were found in the serum of patients with the atypical hyperplasia of endometrium and endometrial carcinoma. | Human | FLT4 | 2324 | fms-related tyrosine kinase 4 | EXPERIMENTAL DESIGN: We assessed the levels of immunoreactivity for VEGF-D and VEGFR-3 in 71 endometrial carcinomas, 14 complex atypical endometrial hyperplasias, and 16 normal endometria by immunohistochemistry. | Human | FIGF | 2277 | c-fos induced growth factor (vascular endothelial growth factor D) | EXPERIMENTAL DESIGN: We assessed the levels of immunoreactivity for VEGF-D and VEGFR-3 in 71 endometrial carcinomas, 14 complex atypical endometrial hyperplasias, and 16 normal endometria by immunohistochemistry. | Human | EP300 | 2033 | E1A binding protein p300 | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | CCNE1 | 898 | cyclin E1 | Cyclin E and p53 expression was studied by immunohistochemistry in eight atypical endometrial hyperplasias (AEHs), 51 endometrioid endometrial carcinomas (EECs), and 22 non-endometrioid endometrial carcinomas (NEECs). | Human | BUB1B | 701 | BUB1 mitotic checkpoint serine/threonine kinase B | Associated endometrial carcinoma, atypical endometrial hyperplasia, uterine leiomyosarcoma, bladder transitional carcinoma, gastric, biliary and renal cell carcinoma | Human | BRAF | 673 | v-raf murine sarcoma viral oncogene homolog B | In addition, mutations of KRAS and p53 and the immunohistochemical expression of hMLH1 and hMSH2 were also examined.RESULTS: Of the 97 carcinomas and 9 hyperplasias, 20 (21%) and 1 (11%) had BRAF mutations, most of them at previously unreported sites. However, the prevalence and significance of BRAF mutations in endometrial carcinoma remain unclear.EXPERIMENTAL DESIGN: We examined BRAF mutations in exons 11 and 15 in 97 cases of endometrial carcinoma (endometrioid type, 78; nonendometrioid type, 19), 9 cases of atypical endometrial hyperplasia, and 20 cases of normal endometrium by direct sequencing. |
|